John Libbey Eurotext

A comprehensive clinico-pathological and genetic evaluation of bottom-of-sulcus focal cortical dysplasia in patients with difficult-to-localize focal epilepsy Volume 21, numéro 1, February 2019

  • [Albers et al., 2011] Albers C.A., Lunter G., MacArthur D.G., McVean G., Ouwehand W.H., Durbin R. Dindel: accurate indel calls from short-read data. Genome Res. 2011;21:961-973.
  • [Barkovich et al., 1997] Barkovich A.J., Kuzniecky R.I., Bollen A.W., Grant P.E. Focal transmantle dysplasia: a specific malformation of cortical development. Neurology. 1997;49:1148-1152.
  • [Baulac et al., 2015] Baulac S., Ishida S., Marsan E. Familial focal epilepsy with focal cortical dysplasia due to mutations. Ann Neurol. 2015;77:675-683. DEPDC5
  • [Bernasconi et al., 2011] Bernasconi A., Bernasconi N., Bernhardt B.C., Schrader D. Advances in MRI for ’cryptogenic’ epilepsies. Nat Rev Neurol. 2011;7:99-108.
  • [Besson et al., 2008] Besson P., Andermann F., Dubeau F., Bernasconi A. Small focal cortical dysplasia lesions are located at the bottom of a deep sulcus. Brain. 2008;131:3246-3255.
  • [Blümcke and Sarnat, 2016] Blümcke I., Sarnat H.B. Somatic mutations rather than viral infection classify focal cortical dysplasia type II as mTORopathy. Curr Opin Neurol. 2016;29:388-395.
  • [Blümcke et al., 2010] Blümcke I., Pieper T., Pauli E. A distinct variant of focal cortical dysplasia type I characterised by magnetic resonance imaging and neuropathological examination in children with severe epilepsies. Epileptic Disord. 2010;12:172-180.
  • [Blümcke et al., 2011] Blümcke I., Thom M., Aronica E. The clinico-pathological spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011;52:158-174.
  • [Blümcke et al., 2016] Blümcke I., Aronica E., Miyata H. International recommendation for a comprehensive neuropathologic workup of epilepsy surgery brain tissue: a consensus Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia. 2016;57:348-358.
  • [Blümcke et al., 2017] Blümcke I., Spreafico R., Haaker G. Histopathological findings in brain tissue obtained during epilepsy surgery. New Engl J Med. 2017;377:1648-1656.
  • [Chassoux et al., 2010] Chassoux F., Rodrigo S., Semah F. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology. 2010;75:2168-2175.
  • [Chassoux et al., 2012] Chassoux F., Landre E., Mellerio C. Type II focal cortical dysplasia: electroclinical phenotype and surgical outcome related to imaging. Epilepsia. 2012;53:349-358.
  • [Colombo et al., 2009] Colombo N., Salamon N., Raybaud C., Ozkara C., Barkovich A.J. Imaging of malformations of cortical development. Epileptic Disord. 2009;11:194-205.
  • [Colombo et al., 2012] Colombo N., Tassi L., Deleo F. Focal cortical dysplasia type IIa and IIb: MRI aspects in 118 cases proven by histopathology. Neuroradiology. 2012;54:1065-1077.
  • [D’Gama et al., 2015] D’Gama A.M., Geng Y., Couto J.A. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol. 2015;77:720-725.
  • [D’Gama et al., 2017] D’Gama A.M., Woodworth M.B., Hossain A.A. Somatic mutations activating the mtor pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias. Cell Rep. 2017;21:3754-3766.
  • [Engel et al., 1993] Engel J Jr, Van Ness PC, Rasmussen TB, Ojemann LM. Outcome with respect to epileptic seizures. In: Surgical treatment of the epilepsies. Engel J Jr. New York: Raven Press, 1993.
  • [EpiPMConsortium, 2015] EpiPMConsortium. A roadmap for precision medicine in the epilepsies. Lancet Neurol. 2015;14:1219-1228.
  • [Epi4Kconsortium, 2017] Epi4Kconsortium. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol. 2017;16:135-143.
  • [Gonzalez-Martinez et al., 2014] Gonzalez-Martinez J., Mullin J., Bulacio J. Stereoelectroencephalography in children and adolescents with difficult-to-localize refractory focal epilepsy. Neurosurgery. 2014;75:258-268. discussion: 67-8
  • [Guerrini et al., 2015] Guerrini R., Duchowny M., Jayakar P. Diagnostic methods and treatment options for focal cortical dysplasia. Epilepsia. 2015;56:1669-1686.
  • [Harvey et al., 2015] Harvey A.S., Mandelstam S.A., Maixner W.J. The surgically remediable syndrome of epilepsy associated with bottom-of-sulcus dysplasia. Neurology. 2015;84:2021-2028.
  • [Huppertz et al., 2005] Huppertz H.J., Grimm C., Fauser S. Enhanced visualization of blurred gray-white matter junctions in focal cortical dysplasia by voxel-based 3D MRI analysis. Epilepsy Res. 2005;67:35-50.
  • [Ishida et al., 2013] Ishida S., Picard F., Rudolf G. Mutations of cause autosomal dominant focal epilepsies. Nat Genet. 2013;45:552-555. DEPDC5
  • [Jamuar et al., 2014] Jamuar S.S., Lam A.T., Kircher M. Somatic mutations in cerebral cortical malformations. New Engl J Med. 2014;371:733-743.
  • [Krsek et al., 2008] Krsek P., Maton B., Korman B. Different features of histopathological subtypes of pediatric focal cortical dysplasia. Ann Neurol. 2008;63:758-769.
  • [Lal et al., 2014] Lal D., Reinthaler E.M., Schubert J. mutations in genetic focal epilepsies of childhood. Ann Neurol. 2014;75:788-792. DEPDC5
  • [Lerner et al., 2009] Lerner J.T., Salamon N., Hauptman J.S. Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia. 2009;50:1310-1335.
  • [Li and Durbin, 2009] Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
  • [Li and Wang, 2017] Li Q., Wang K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP Guidelines. Am J Hum Genet. 2017;100:267-280.
  • [Li et al., 2009] Li H., Handsaker B., Wysoker A. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078-2079.
  • [Lim et al., 2015] Lim J.S., Kim W.I., Kang H.C. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nature Med. 2015;21:395-400.
  • [Louis et al., 2016] Louis D.N., Perry A., Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-820.
  • [Ma et al., 2013] Ma D., Gulani V., Seiberlich N. Magnetic resonance fingerprinting. Nature. 2013;495:187-192.
  • [Marsan and Baulac, 2018] Marsan E., Baulac S. Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathol Appl Neurobiol. 2018;44:6-17.
  • [McKenna et al., 2010] McKenna A., Hanna M., Banks E. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-1303.
  • [Mellerio et al., 2014] Mellerio C., Labeyrie M.A., Chassoux F. 3T MRI improves the detection of transmantle sign in type 2 focal cortical dysplasia. Epilepsia. 2014;55:117-122.
  • [Mirzaa et al., 2016] Mirzaa G.M., Campbell C.D., Solovieff N. Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism. JAMA Neurol. 2016;73:836-845.
  • [Moller et al., 2016] Moller R.S., Weckhuysen S., Chipaux M. Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet. 2016;2:e118.
  • [Najm et al., 2018] Najm I.M., Sarnat H.B., Blümcke I. Review: the international consensus classification of focal cortical dysplasia - a critical update 2018. Neuropathol Appl Neurobiol. 2018;44:18-31.
  • [Ribierre et al., 2018] Ribierre T., Deleuze C., Bacq A. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest. 2018;128:2452-2458.
  • [Richards et al., 2015] Richards S., Aziz N., Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
  • [Rimmer et al., 2014] Rimmer A., Phan H., Mathieson I. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014;46:912-918.
  • [Robinson et al., 2011] Robinson J.T., Thorvaldsdottir H., Winckler W. Integrative genomics viewer. Nature Biotech. 2011;29:24-26.
  • [Scheffer et al., 2014] Scheffer I.E., Heron S.E., Regan B.M. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol. 2014;75:782-787.
  • [Urbach et al., 2002] Urbach H., Scheffler B., Heinrichsmeier T. Focal cortical dysplasia of Taylor's balloon cell type: a clinicopathological entity with characteristic neuroimaging and histopathological features, and favorable postsurgical outcome. Epilepsia. 2002;43:33-40.
  • [Vogelstein et al., 2013] Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A. Jr., Kinzler K.W. Cancer genome landscapes. Science. 2013;339:1546-1558.
  • [Wagner et al., 2011] Wagner J., Weber B., Urbach H., Elger C.E., Huppertz H.J. Morphometric MRI analysis improves detection of focal cortical dysplasia type II. Brain. 2011;134:2844-2854.
  • [Wang et al., 2014] Wang Z.I., Alexopoulos A.V., Jones S.E. Linking MRI postprocessing with magnetic source imaging in MRI-negative epilepsy. Ann Neurol. 2014;75:759-770.
  • [Wang et al., 2015] Wang Z.I., Jones S.E., Jaisani Z. Voxel-based morphometric magnetic resonance imaging (MRI) postprocessing in MRI-negative epilepsies. Ann Neurol. 2015;77:1060-1075.